Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com

StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a sell rating to a hold rating in a research note published on Wednesday.

Other equities analysts have also issued research reports about the company. Robert W. Baird decreased their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Down 4.2 %

NASDAQ ENTA opened at $8.03 on Wednesday. Enanta Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $17.80. The firm has a market cap of $171.28 million, a PE ratio of -1.62 and a beta of 0.54. The business’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $9.26.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Research analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Buying and Selling

In related news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 13.89% of the stock is owned by insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ENTA. Tower Research Capital LLC TRC increased its stake in shares of Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after buying an additional 2,274 shares during the period. AlphaQuest LLC grew its holdings in Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares in the last quarter. Invesco Ltd. increased its position in shares of Enanta Pharmaceuticals by 7.3% in the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 3,186 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Enanta Pharmaceuticals by 10.5% in the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 3,501 shares in the last quarter. Finally, US Bancorp DE lifted its position in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,243 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.